HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

N- (3- (4- chlorophenyl)- 2- (3- cyanophenyl)- 1- methylpropyl)- 2- methyl- 2- ((5- (trifluoromethyl)pyridin- 2- yl)oxy)propanamide

MK-0364 is the (1S,2S)-isomer; a cannabinoid-1 receptor inverse agonist; structure in first source
Also Known As:
MK 0364; MK-0364; MK0364; taranabant
Networked: 31 relevant articles (5 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Addy, Carol: 7 articles (08/2012 - 01/2008)
2. Rosko, Kim: 6 articles (08/2012 - 01/2008)
3. Li, Susie: 6 articles (10/2010 - 04/2008)
4. Yuan, Jinyu: 6 articles (02/2009 - 01/2008)
5. Wagner, John: 5 articles (08/2012 - 01/2008)
6. Dunbar, Stephanie: 5 articles (08/2012 - 06/2008)
7. Li, Hankun: 4 articles (12/2010 - 04/2008)
8. Gantz, Ira: 4 articles (12/2010 - 01/2008)
9. Wagner, John A: 4 articles (10/2010 - 11/2008)
10. Stoch, Aubrey: 4 articles (10/2010 - 01/2008)

Related Diseases

1. Weight Loss (Weight Reduction)
2. Overweight
3. Abdominal Pain (Pain, Abdominal)
4. Obesity
5. Nausea
04/01/2010 - "Compared to placebo, taranabant 2-8 mg was associated with an increased incidence of psychiatric-related adverse events (e.g., depression, 8.2% versus 2.5%, P = 0.048), gastrointestinal-related adverse events (e.g., nausea, 49.7% versus 19.0%, P < 0.001), and flushing/hot flash adverse events (10.7% versus 1.9%, P = 0.002). "
11/01/2010 - "However, there may also be undesirable side effects (e.g., nausea, malaise, anxiety, and depression) that are produced by the current generation of CB1 inverse agonists such as rimonabant and taranabant. "
06/01/2010 - "After 52 weeks, the incidences of adverse experiences classified in the gastrointestinal (diarrhoea, nausea, vomiting), nervous system-related (dizziness, sensory-related), and psychiatric (irritability, depression-related) organ systems were numerically higher or statistically significantly higher in all taranabant groups compared with the placebo group. "
08/01/2010 - "Incidences of adverse experiences classified in the gastrointestinal (diarrhea and nausea), nervous system (dizziness/dizziness postural), psychiatric-related (irritability and anger/aggression) and vascular (flushing/hot flush) organ systems were higher and statistically significant in the taranabant 2-mg group compared with the placebo group. "
03/01/2009 - "However, rimonabant's market withdrawal in the European Union and suspension of rimonabant's, taranabant's, and otenabant's ongoing development programs have highlighted some adverse clinical side effects (especially nausea and psychiatric disturbances) of CB1 receptor antagonists/inverse agonists. "

Related Drugs and Biologics

1. rimonabant
2. CB1 Cannabinoid Receptor (CB1 Receptor)
3. Bupropion (Wellbutrin)
4. Phentermine (Adipex-P)
5. Naltrexone (ReVia)
6. Digoxin (Digitek)
7. Diethylpropion (Amfepramone)
8. Tesofensine
9. 8- chloro- 2,3,4,5- tetrahydro- 1- methyl- 1H- 3- benzazepine
10. pramlintide (Symlin)

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Caloric Restriction
3. Therapeutics
4. Stents